Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells

Asian Journal of Andrology

Volumn 18, Issue 4, 2016, Pages 607-612

  Tian, Yuantong ^a,b   Zhao, Lijing ^a   Wang, Ye ^a   Zhang, Haitao ^c   Xu, Duo ^a   Zhao, Xuejian ^a   Li, Yi ^a   Li, Jing ^a  

^a JILIN UNIVERSITY   (China)

^b GANNAN MEDICAL UNIVERSITY   (China)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aldo keto reductase family 1 member C3; androgen; berberine; castration resistant prostate cancer

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; BERBERINE; MESSENGER RNA; OXIDOREDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN;

ANDROGEN SYNTHESIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME INHIBITION; GENE EXPRESSION; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR INTERACTION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN INTERACTION; BIOSYNTHESIS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MALE; METABOLISM; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

3-HYDROXYSTEROID DEHYDROGENASES; BERBERINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84977639999     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.169997     Document Type: Article

References (26)

1. Titus M, Tomer KB. Androgen quantitation in prostate cancer tissue using liquid chromatography tandem mass spectrometry. Methods Mol Biol 2011; 776: 47-57
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-16
3. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 243-58
4. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-15
5. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54
6. Pezaro CJ, Mukherji D, De Bono JS. Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discov Today 2012; 17: 221-6
7. Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 2012; 6: 13-8
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
9. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71
10. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, et al. Hormonal impact of the 17alpha-hydroxylase/C (17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90: 2317-25
11. Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 2013; 137: 136-49
12. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12: 101-7
13. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001; 26: 11-9
14. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, et al. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 2008; 617: 529-34
15. Tian Y, Zhao L, Zhang H, Liu X, Zhao X, et al. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol 2014; 9: 42
16. Byrns MC, Mindnich R, Duan L, Penning TM. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J Steroid Biochem Mol Biol 2012; 130: 7-15
17. Byrns MC, Jin Y, Penning TM. Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J Steroid Biochem Mol Biol 2011; 125: 95-104
18. Wang Y, Liu Q, Liu Z, Li B, Sun Z, et al. Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells. Mutat Res 2012; 734: 20-9
19. Li J, Cao B, Liu X, Fu X, Xiong Z, et al. Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther 2011; 10: 1346-56
20. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 2006; 5: 296-308
21. Loriot Y, Fizazi K, Jones RJ, Van den Brande J, Molife RL, et al. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs 2014; 32: 995-1004
22. Yin YD, Fu M, Brooke DG, Heinrich DM, Denny WA, et al. The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17beta-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer. Front Oncol 2014; 4: 159
23. Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, et al. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 2009; 34: 1221-30
24. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-25
25. Schlegel BP, Jez JM, Penning TM. Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases. Biochemistry 1998; 37: 3538-48
26. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, et al. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 2005; 67: 60-8